Literature DB >> 18206551

Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning.

Stephen J Wolf, Eric J Lavonas, Edward P Sloan, Andy S Jagoda.   

Abstract

This clinical policy focuses on critical issues concerning the management of adult patients presenting to the emergency department (ED) with acute symptomatic carbon monoxide (CO) poisoning. The subcommittee reviewed the medical literature relevant to the questions posed. The critical questions are: Should hyperbaric oxygen (HBO2) therapy be used for the treatment of patients with acute CO poisoning; and Can clinical or laboratory criteria identify CO-poisoned patients who are most or least likely to benefit from this therapy. Recommendations are provided on the basis of the strength of evidence of the literature. Level A recommendations represent patient management principles that reflect a high degree of clinical certainty; Level B recommendations represent patient management principles that reflect moderate clinical certainty; and Level C recommendations represent other patient management strategies that are based on preliminary, inconclusive, or conflicting evidence, or based on committee consensus. This clinical policy is intended for physicians working in hospital-based EDs.

Entities:  

Mesh:

Year:  2008        PMID: 18206551     DOI: 10.1016/j.annemergmed.2007.10.012

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  19 in total

1.  The syndrome of delayed post-hypoxic leukoencephalopathy.

Authors:  David Shprecher; Lahar Mehta
Journal:  NeuroRehabilitation       Date:  2010       Impact factor: 2.138

Review 2.  Hyperbaric oxygen for carbon monoxide poisoning.

Authors:  Nick A Buckley; David N Juurlink; Geoff Isbister; Michael H Bennett; Eric J Lavonas
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  Clinical Outcomes and Mortality Impact of Hyperbaric Oxygen Therapy in Patients With Carbon Monoxide Poisoning.

Authors:  Jason J Rose; Mehdi Nouraie; Marc C Gauthier; Anthony F Pizon; Melissa I Saul; Michael P Donahoe; Mark T Gladwin
Journal:  Crit Care Med       Date:  2018-07       Impact factor: 7.598

4.  Complications of carbon monoxide poisoning: a case discussion and review of the literature.

Authors:  Davin K Quinn; Shunda M McGahee; Laura C Politte; Gina N Duncan; Cristina Cusin; Christopher J Hopwood; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Hazards of Hawai'i Volcanoes National Park.

Authors:  Gregory M Sprowl
Journal:  Hawaii J Med Public Health       Date:  2014-11

Review 6.  Carbon Monoxide and Cyanide Poisoning in the Burned Pregnant Patient: An Indication for Hyperbaric Oxygen Therapy.

Authors:  Derek M Culnan; Beretta Craft-Coffman; Genevieve H Bitz; Karel D Capek; Yiji Tu; William C Lineaweaver; Maggie J Kuhlmann-Capek
Journal:  Ann Plast Surg       Date:  2018-03       Impact factor: 1.539

7.  Carbon monoxide toxicity after lighting coals at a hookah bar.

Authors:  Ryan Misek; Christine Patte
Journal:  J Med Toxicol       Date:  2014-09

8.  Delayed neuropsychological sequelae after carbon monoxide poisoning: predictive risk factors in the Emergency Department. A retrospective study.

Authors:  Giuseppe Pepe; Matteo Castelli; Peiman Nazerian; Simone Vanni; Massimo Del Panta; Francesco Gambassi; Primo Botti; Andrea Missanelli; Stefano Grifoni
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2011-03-17       Impact factor: 2.953

Review 9.  Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy.

Authors:  Jason J Rose; Ling Wang; Qinzi Xu; Charles F McTiernan; Sruti Shiva; Jesus Tejero; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

10.  Rapid elimination of CO through the lungs: coming full circle 100 years on.

Authors:  Joseph A Fisher; Steve Iscoe; Ludwik Fedorko; James Duffin
Journal:  Exp Physiol       Date:  2011-10-03       Impact factor: 2.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.